This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, X. Articles by Conney, A. H. Search for Related Content PubMed PubMed Citation Articles by Zheng, X. Articles by Conney, A. H.

Inhibitory Effect of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans-Retinoic Acid on the Growth of LNCaP Prostate Tumors in Immunodeficient Mice

¹ Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey; ² Division of Biometrics, School of Public Health, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey; ³ Cancer Institute of New Jersey, New Brunswick, New Jersey; ⁴ Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey; and ⁵ Center for Advanced Biotechnology and Medicine and the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey

Clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate (TPA; 0.16–0.32 nM) and all-trans-retinoic acid (ATRA; 0.5–1 µM) had a synergistic inhibitory effect on the growth of cultured LNCaP prostate cancer cells, and apoptosis was markedly stimulated. In additional studies, NCr immunodeficient mice received s.c. injection with LNCaP cells in Matrigel. After 4–6 weeks, mice with well-established tumors received i.p. injection with vehicle, TPA (0.16 nmol/g body weight), ATRA (0.5 nmol/g body weight), or TPA+ATRA in vehicle once a day for 46 days. Tumor growth occurred in all of the vehicle-treated control mice. The percentage of animals with some tumor regression after 21 days of treatment was 0% for the control group, 31% for the ATRA group, 62% for the TPA group, and 100% for the TPA+ATRA group (13 mice/group). Although treatment of the mice with TPA or TPA+ATRA continued to inhibit tumor growth for the duration of the 46-day study, treatment of the mice with ATRA alone did not inhibit tumor growth beyond 28 days of daily injections (6 mice/group). Mechanistic studies indicated that treatment of the mice with TPA or TPA+ATRA for 46 days increased apoptosis in the tumors, and treatment with TPA+ATRA also decreased the mitotic index. Because the dose of TPA used in this study was effective and resulted in clinically achievable blood levels, clinical trials with TPA alone or in combination with ATRA in patients with prostate cancer may be warranted.

This article has been cited by other articles:

				M. Mancuso, E. Pasquali, S. Leonardi, M. Tanori, S. Rebessi, V. Di Majo, S. Pazzaglia, M. P. Toni, M. Pimpinella, V. Covelli, et al. From the Cover: Oncogenic bystander radiation effects in Patched heterozygous mouse cerebellum PNAS, August 26, 2008; 105(34): 12445 - 12450. [Abstract] [Full Text] [PDF]

				X. Zheng, X.-X. Cui, G. E. Avila, M.-T. Huang, Y. Liu, J. Patel, A. N. T. Kong, R. Paulino, W. J. Shih, Y. Lin, et al. Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice Clin. Cancer Res., September 15, 2007; 13(18): 5480 - 5487. [Abstract] [Full Text] [PDF]

				X. Zheng, R. L. Chang, X.-X. Cui, G. E. Avila, V. Hebbar, M. Garzotto, W. J. Shih, Y. Lin, S.-E. Lu, A. B. Rabson, et al. Effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) in Combination with Paclitaxel (Taxol) on Prostate Cancer LNCaP Cells Cultured In vitro or Grown as Xenograft Tumors in Immunodeficient Mice. Clin. Cancer Res., June 1, 2006; 12(11): 3444 - 3451. [Abstract] [Full Text] [PDF]

				T. O. Khor, Y.-S. Keum, W. Lin, J.-H. Kim, R. Hu, G. Shen, C. Xu, A. Gopalakrishnan, B. Reddy, X. Zheng, et al. Combined Inhibitory Effects of Curcumin and Phenethyl Isothiocyanate on the Growth of Human PC-3 Prostate Xenografts in Immunodeficient Mice Cancer Res., January 15, 2006; 66(2): 613 - 621. [Abstract] [Full Text] [PDF]

				A. M. Gonzalez-Guerrico and M. G. Kazanietz Phorbol Ester-induced Apoptosis in Prostate Cancer Cells via Autocrine Activation of the Extrinsic Apoptotic Cascade: A KEY ROLE FOR PROTEIN KINASE C{delta} J. Biol. Chem., November 25, 2005; 280(47): 38982 - 38991. [Abstract] [Full Text] [PDF]

				G. E. Avila, X. Zheng, X. X. Cui, A. D. Ryan, A. Hansson, J. Suh, A. B. Rabson, R. L. Chang, W. J. Shih, Y. Lin, et al. Inhibitory Effects of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans Retinoic Acid on the Growth of Cultured Human Pancreas Cancer Cells and Pancreas Tumor Xenografts in Immunodeficient Mice J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 170 - 187. [Abstract] [Full Text] [PDF]